Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma

• Autores: Rioja, Patricia, Rey-Cardenas, M, De Velasco, Guillermo
• Formato: artículo
• Fecha de Publicación: 2025
• Institución: Instituto Nacional de Enfermedades Neoplásicas
• Repositorio: INEN-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.inen.sld.pe:20.500.14703/475
• Enlace del recurso: https://doi.org/10.1016/j.ctrv.2024.102801; https://hdl.handle.net/20.500.14703/475
• Nivel de acceso: acceso abierto
• Materia: anemia; cell carcinoma; https://purl.org/pe-repo/ocde/ford#3.02.30

Renal cell carcinoma (RCC) is a heterogenous disease which the incidence is increasing worldwide. The identification and understanding of the role of the Von Hipple Lindau (VHP) in regulating the hypoxia-inducible factor signaling pathway has revolutionized the treatment of this disease. Belzutifan is an oral hypoxiainducible factor (HIF)-2α inhibitor, which has demonstrated efficacy in treating von Hippel-Lindau (VHL) disease and for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1– and VEGFR-targeted therapies. One of the most common adverse effect of this drug is anemia; however, it is treatment is not well known. This review summarizes role of the VHL-HIF pathway in ccRCC aroused the interest of targeting HIF activity, the history of belzutifan development and their relationship to anemia as well as propose a management algorithm